Optiscan has been featured in Stockhead’s Health Check segment following the announcement that its cloud-based telepathology streaming software, developed in collaboration with Canadian partner Prolucid Technologies, has progressed to Minimum Viable Product (MVP) stage.

The software enables pathologists to review high-resolution images, generate reports, and collaborate securely with clinicians—even during live surgical procedures. This advancement supports immediate, informed decision-making and removes traditional barriers between pathology and surgery.

Optiscan CEO Dr Camile Farah said, “This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural and remote healthcare settings where access to pathology expertise is limited.”

This milestone represents a key step in delivering secure, real-time collaboration and further advancing the Company’s digital health capabilities.

Read the full article here.